Skip to Content

Improvement of QoL for patients with Relapsed/Refractory Large B-Cell Lymphoma in CAR T-cell therapy

In this MEDtalk, Mahmoud Elsawy, MD, MSc, Queen Elizabeth II Health Sciences Centre and Dalhouse University, Canada, presents data from the ZUMA-7 study, the first randomized, global, multicenter Phase 3 study of axicabtagene Ciloleucel CAR T-cell therapy vs. standard of care treatment. The study shows a clinically meaningful improvement in QoL vs. standard of care at Day 100.

Mahmoud Elsawy

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top